SUNMMIO's 3D AI Inference Chips Draw Beijing State Capital

Beijing-based SUNMMIO, known in China as 算苗科技, has completed Pre-A2 and Series A financings with backing from government-affiliated investment platforms, including Yizhuang State-Owned Capital Investment. The company did not separately disclose how much the newly announced rounds raised, and its release did not independently establish their combined value.

What SUNMMIO did report is a cumulative figure: nearly RMB 2 billion raised across multiple rounds over the past year. That total covers more than the transactions announced this week and should not be read as the size of the new financing. No valuation was company-confirmed.

The company develops 3D TokenPU processors aimed at AI inference, the process of running trained models. Its approach vertically stacks memory wafers above computing circuitry to shorten the distance data must travel. SUNMMIO says its first A4E processor completed tapeout in June and is designed to deliver 16 terabytes per second of memory bandwidth.

The raise lands in the middle of China's effort to build domestic alternatives for AI computing. Rather than reproducing conventional graphics processors, SUNMMIO is betting that a different architecture can address the memory constraints that increasingly shape inference costs and performance. It was one of two Chinese companies in the day's broader funding roundup, alongside Guangzhou-based robotics developer Yundie Technology — a pairing that illustrates capital moving into both the chip layer and the physical deployment layer of the AI economy.

Investors elsewhere were applying similar logic. Across the ten startup funding announcements tracked that day, eight companies disclosed precise dollar-denominated rounds totaling $503.5 million, with the largest checks going to businesses tied to expensive real-world problems rather than general-purpose software: Austin's ICON pulled in $200 million for robotic construction, and Boston's Soufflé Therapeutics raised $135 million for RNA-based medicines. Seven of the selected companies were based in the United States, one in Israel, and two in China.

The open question for SUNMMIO is the one that hangs over every chip startup with impressive published specifications. Tapeout and a headline bandwidth number are engineering milestones, not commercial proof. They do not establish volume-production yields, competitive pricing, or performance inside real customer deployments — the metrics that ultimately decide whether an architecture advantage converts into orders. Until the company discloses how much the new rounds raised and how its silicon performs outside the lab, the nearly RMB 2 billion figure remains the clearest measure of investor conviction it has offered.